BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Identification of mitochondrial genome concatemers in AIDS-associated lymphomas and lymphoid cell lines.

Since most oncogenic viruses persist as extrachromosomal covalently closed circular DNA (cccDNA) in tumor cells, we developed an assay to visualize and identify cccDNA in primary lymphomas.

One AIDS-associated lymphoma (EL) was further studied in detail as its mitochondrial genome consisted of tandem head-to-tail duplications.

Insertion of C-residues was noted near the origin of replication of EL mtDNA.

EL cells responded weakly to Fas-apoptotic stimulus, displayed reduced mitochondrial activity and mass, and produced higher levels of reactive oxygen intermediates.

Screening of several AIDS-associated lymphomas and established lymphoid cell lines also revealed the presence of mitochondrial genome concatemers consisting of interlinked monomer molecules.

Taken together, our results suggest that formation of mtDNA concatemers is associated with oncogenic transformation in lymphoid cells.

Genetic Alliance. consumer health - AIDS-HIV.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14453-8 [18796602.001]

[Cites] Cancer Res. 2001 Oct 1;61(19):7015-9 [11585726.001]

[Cites] J Clin Pathol. 2003 Mar;56(3):188-92 [12610094.001]

[Cites] Bone Marrow Transplant. 2003 Feb;31(3):145-55 [12621474.001]

[Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]

[Cites] IUBMB Life. 2003 Apr-May;55(4-5):213-7 [12880201.001]

[Cites] Mol Genet Genomics. 2003 Jul;269(4):454-63 [12768414.001]

[Cites] Science. 2004 May 14;304(5673):981 [15143273.001]

[Cites] Biopolymers. 1970;9(3):373-9 [5417647.001]

[Cites] J Virol. 1984 Apr;50(1):248-54 [6321792.001]

[Cites] J Virol. 1989 Sep;63(9):3601-11 [2547988.001]

[Cites] Antimicrob Agents Chemother. 1994 Dec;38(12):2743-9 [7695256.001]

[Cites] Nucleic Acids Res. 1996 Oct 15;24(20):4084-91 [8918816.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1172-6 [9037025.001]

[Cites] Nature. 1997 Apr 3;386(6624):517-21 [9087414.001]

[Cites] Nucleic Acids Res. 1998 Feb 15;26(4):967-73 [9461455.001]

[Cites] Biochem Z. 1962;336:281-98 [14003030.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):719-24 [15647368.001]

[Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]

[Cites] Biochim Biophys Acta. 2006 May-Jun;1757(5-6):700-7 [16782042.001]

[Cites] Cold Spring Harb Symp Quant Biol. 2005;70:363-74 [16869773.001]

[Cites] Oncogene. 2006 Aug 7;25(34):4647-62 [16892079.001]

[Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]

[Cites] J Infect Dis. 2007 May 15;195(10):1419-25 [17436221.001]

[Cites] Proc Natl Acad Sci U S A. 2007 May 22;104(21):9001-6 [17517629.001]

[Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4331-5 [17671113.001]

[Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]

[Cites] Methods Mol Biol. 2007;372:153-66 [18314724.001]

[Cites] Cancer Lett. 2008 Jul 18;266(1):30-6 [18372105.001]

[Cites] Cancer Lett. 2008 Jul 18;266(1):21-9 [18374479.001]

[Cites] Nature. 2000 Oct 12;407(6805):789-95 [11048730.001]

(PMID = 19362738.001).

[ISSN] 1873-5835

[Journal-full-title] Leukemia research

[ISO-abbreviation] Leuk. Res.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA111196-04; United States / NCI NIH HHS / CA / CA111196-02; United States / NCI NIH HHS / CA / R01CA111196; United States / NCI NIH HHS / CA / R01 CA111196-01A2; United States / NCI NIH HHS / CA / CA111196-03; United States / NCI NIH HHS / CA / R01 CA111196-03; United States / NCI NIH HHS / CA / CA111196-04; United States / NCI NIH HHS / CA / R01 CA111196; United States / NCI NIH HHS / CA / R01 CA111196-02; United States / NCI NIH HHS / CA / CA111196-01A2

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Mitochondrial

[Other-IDs] NLM/ NIHMS103972; NLM/ PMC2730422

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Differential gene expression in HIV/SIV-associated and spontaneous lymphomas.

Diffuse large B-cell lymphoma (DLBCL) is more prevalent and more often fatal in HIV-infected patients and SIV-infected monkeys compared to immune-competent individuals.

Molecular, biological, and immunological data indicate that virus-associated lymphomagenesis is similar in both infected hosts.

To find genes specifically overexpressed in HIV/SIV-associated and non-HIV/SIV-associated DLBCL we compared gene expression profiles of HIV/SIV-related and non-HIV-related lymphomas using subtractive hybridization and Northern blot analysis.

Our experimental approach allowed us to detect two genes (a-myb and pub) upregulated solely in HIV/SIV-associated DLBCLs potentially involved in virus-specific lymphomagenesis in human and monkey.

Downregulation of the pub gene was observed in all non-HIV-associated lymphomas investigated.

In addition, we have found genes upregulated in both non-HIV- and HIV-associated lymphomas.

In summary, we have demonstrated that simultaneous transcriptional upregulation of at least two genes (a-myb and pub) was specific for AIDS-associated lymphomas.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] FEMS Immunol Med Microbiol. 1999 Dec;26(3-4):227-32 [10575133.001]

[Cites] Blood. 1998 May 1;91(9):3103-11 [9558363.001]

[Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]

[Cites] J Biol Chem. 2000 Mar 3;275(9):6499-508 [10692454.001]

[Cites] Curr Opin Immunol. 2000 Apr;12(2):219-25 [10712950.001]

[Cites] Clin Cancer Res. 2000 Jun;6(6):2456-63 [10873099.001]

[Cites] Blood. 2000 Jul 15;96(2):398-404 [10887098.001]

[Cites] Blood. 2000 Aug 1;96(3):1013-20 [10910917.001]

[Cites] J Biol Chem. 2001 Jun 22;276(25):22709-14 [11331269.001]

[Cites] Eur J Cancer. 2001 Jul;37(10):1236-50 [11423256.001]

[Cites] Int J Cancer. 2001 Dec 20;96(6):327-33 [11745502.001]

[Cites] Blood. 2002 Sep 1;100(5):1802-9 [12176903.001]

[Cites] Med Hypotheses. 2002 Dec;59(6):670-3 [12445508.001]

[Cites] Oncogene. 2003 Feb 6;22(5):769-74 [12569370.001]

[Cites] Biochem Biophys Res Commun. 2003 Apr 11;303(3):940-6 [12670502.001]

[Cites] Exp Mol Pathol. 2003 Apr;74(2):129-39 [12710944.001]

[Cites] J Exp Med. 1992 Jul 1;176(1):281-6 [1319458.001]

[Cites] Biochem Biophys Res Commun. 2003 Nov 14;311(2):351-60 [14592421.001]

[Cites] Clin Immunol. 2003 Nov;109(2):119-29 [14597210.001]

[Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]

[Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4279-83 [7753797.001]

[Cites] Int J Cancer. 1995 May 16;61(4):574-9 [7759163.001]

[Cites] DNA Res. 1995 Aug 31;2(4):167-74, 199-210 [8590280.001]

[Cites] J Biol Chem. 1996 May 10;271(19):11059-62 [8626647.001]

[Cites] J Biol Chem. 1997 Jul 4;272(27):16729-32 [9201974.001]

[Cites] Int J Cancer. 1997 Jul 3;72(1):160-5 [9212238.001]

[Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]

[Cites] AIDS Res Hum Retroviruses. 1997 Dec 10;13(18):1589-96 [9430251.001]

[Cites] AIDS Res Hum Retroviruses. 2000 Jan 20;16(2):173-9 [10659056.001]

(PMID = 16239949.001).

[ISSN] 1449-1907

[Journal-full-title] International journal of medical sciences

[ISO-abbreviation] Int J Med Sci

[Language] eng

[Publication-type] Journal Article

[Publication-country] Australia

[Other-IDs] NLM/ PMC1252723

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The CD38 molecule is well represented on cell surfaces in many cases of a variety of lymphoid tumors, notably multiple myeloma, AIDS-associated lymphomas, and post-transplant lymphoproliferations.

[MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Cell Line, Tumor. Humans. Leukemia / immunology. Lymphoma, B-Cell / immunology. Mice. Mice, SCID. Multiple Myeloma / immunology. Transplantation, Heterologous

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Leuk Res. 2001 Jan;25(1):1-12 [11137554.001]

[Cites] Mol Cancer Ther. 2004 Mar;3(3):345-52 [15026555.001]

[Cites] Scand J Immunol. 1978 Apr;7(4):297-306 [418499.001]

[Cites] Am J Hematol. 1990 Feb;33(2):101-9 [2301368.001]

[Cites] Blood. 1991 Mar 1;77(5):1071-9 [1995092.001]

[Cites] Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):352-6 [8380497.001]

[Cites] Blood. 1994 Sep 1;84(5):1442-9 [7520771.001]

[Cites] Blood. 1994 Nov 1;84(9):3017-25 [7524764.001]

[Cites] Blood. 2005 Sep 1;106(5):1762-9 [15905193.001]

[Cites] Leuk Res. 2007 Apr;31(4):455-63 [16920192.001]

(PMID = 17380203.001).

[ISSN] 1076-1551

[Journal-full-title] Molecular medicine (Cambridge, Mass.)

[ISO-abbreviation] Mol. Med.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; EC 3.2.2.5 / Antigens, CD38

[Other-IDs] NLM/ PMC1829201

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Epstein-Barr virus (EBV) causes EBV-associated lymphoproliferative diseases in patients with profound immune suppression.

Most of these diseases are life-threatening and the prognosis of AIDS-associated lymphomas is extremely unfavorable.

We investigated the possibility of nuclear factor kappa B (NF-kappaB) inhibition by dehydroxymethylepoxyquinomicin (DHMEQ) for the treatment and prevention of EBV-associated lymphoproliferative diseases.

These results suggest that NF-kappaB is a molecular target for the treatment and prevention of EBV-associated lymphoproliferative diseases.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18538617.001).

[ISSN] 1286-4579

[Journal-full-title] Microbes and infection

[ISO-abbreviation] Microbes Infect.

[Language] ENG

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] France

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Cyclohexanones; 0 / Immunologic Factors; 0 / NF-kappa B; 0 / dehydroxymethylepoxyquinomicin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Liposomal doxorubicin, cyclophosphamide, and etoposide and antiretroviral therapy for patients with AIDS-related lymphoma: a pilot study.

PURPOSE: To evaluate in a pilot study the safety and efficacy of liposomal doxorubicin, cyclophosphamide, and etoposide (LACE) when combined with antiretroviral therapy (ART) in patients with AIDS-related lymphoma (ARL).

The impact of HIV viral control on therapy and survival was also assessed.

RESULTS: The median patient CD4+ count was 190 cells/microl (range, 20-510 cells/microl), and the median HIV viral load (VL) was 61,613 copies/ml (range, <50-500,000 copies/ml).

Six patients (50%) were ART-naïve, five were viremic despite ART, and one had an undetectable HIV-1 VL.

HIV viral control can be maintained in the majority of patients during and after completion of LACE.

[MeSH-major] Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. ETOPOSIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16794245.001).

[ISSN] 1083-7159

[Journal-full-title] The oncologist

[ISO-abbreviation] Oncologist

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Drug Carriers; 0 / Liposomes; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; ACE protocol 1

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Novel virally targeted therapies of EBV-associated tumors.

EBV is associated to the development of several malignancies of lymphoid and epithelial origin, including Burkitt's Lymphoma, post-transplant lymphoproliferative disorders, Hodgkin's disease, AIDS-associated lymphomas, NK/T cell lymphoma and Nasopharyngeal carcinoma.

EBV genes play an essential role in the development of the malignant phenotype and therefore molecules interfering with the function of these genes may represent an essential tool to treat EBV-associated malignancies.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18991568.001).

[ISSN] 1873-5576

[Journal-full-title] Current cancer drug targets

[ISO-abbreviation] Curr Cancer Drug Targets

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Antiviral Agents

[Number-of-references] 122

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV-1 nef protein visits B-cells via macrophage nanotubes: a mechanism for AIDS-related lymphoma pathogenesis?

This letter refers to the recent demonstration that HIV-1 infected macrophages form specialized conduits that connect to B-cells (1).

The conduit selectively transports the HIV-1 nef protein, providing nef with numerous means to interfere with cellular processes.

Currently, no consideration of the connection between the conduit and the development of AIDS-related lymphoma (ARL) has been offered.

ARL is one of the primary causes of death in the HIV-infected population and is related to B-cell proliferation and activation.

In this letter we discuss several studies that link HIV-infected macrophages and specific forms of the nef protein to the development of ARL.

The conduits discovered by Xu et al. may lead to a better understanding of how HIV infection results in lymphomagenesis.

[MeSH-major] B-Lymphocytes / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / physiopathology. Macrophages / immunology. nef Gene Products, Human Immunodeficiency Virus / metabolism

[MeSH-minor] HIV Infections / immunology. HIV Infections / virology. HIV-1 / physiology. Humans

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - HIV.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cell Host Microbe. 2008 Jul 17;4(1):63-76 [18621011.001]

[Cites] IEEE/ACM Trans Comput Biol Bioinform. 2008 Apr-Jun;5(2):291-300 [18451438.001]

[Cites] Nat Immunol. 2009 Sep;10(9):933-4 [19692990.001]

[Cites] Nat Immunol. 2009 Sep;10(9):1008-17 [19648924.001]

[Cites] Hum Immunol. 2009 May;70(5):325-30 [19236898.001]

[Cites] Nucleic Acids Res. 2009 Oct;37(19):6575-86 [19729508.001]

[Cites] PLoS One. 2009;4(12):e8153 [19997510.001]

[Cites] Immunol Cell Biol. 2010 Jan;88(1):1-2 [19859083.001]

[Cites] J Leukoc Biol. 2010 Apr;87(4):599-608 [20042468.001]

[Cites] J Leukoc Biol. 2010 Apr;87(4):627-32 [20042471.001]

[Cites] Retrovirology. 2010;7:33 [20380696.001]

[Cites] J Immunol. 2009 Aug 15;183(4):2415-24 [19620308.001]

[Cites] J Virol. 2001 Apr;75(8):3657-65 [11264355.001]

[Cites] Nat Rev Immunol. 2003 Feb;3(2):97-107 [12563294.001]

[Cites] Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):5011-5 [1711215.001]

[Cites] Virology. 1993 Nov;197(1):420-5 [8212577.001]

[Cites] AIDS Res Hum Retroviruses. 1994 Aug;10(8):1003-10 [7811531.001]

[Cites] Cell. 1996 Jun 14;85(6):931-42 [8681387.001]

[Cites] Res Virol. 1997 Jan-Feb;148(1):68-70 [9017838.001]

[Cites] Clin Rev Allergy Immunol. 1996-1997 Winter;14(4):359-66 [9040966.001]

[Cites] Eur J Biochem. 1997 Aug 1;247(3):843-51 [9288906.001]

[Cites] Nat Med. 1999 Sep;5(9):997-103 [10470075.001]

[Cites] J Biol Chem. 2004 Dec 3;279(49):51688-96 [15459189.001]

[Cites] J Gen Virol. 2006 Mar;87(Pt 3):563-71 [16476977.001]

[Cites] Exp Cell Res. 2006 Nov 1;312(18):3659-68 [16978607.001]

[Cites] Virology. 2006 Nov 25;355(2):175-91 [16916529.001]

[Cites] J Leukoc Biol. 2008 May;83(5):1136-44 [18285406.001]

[Cites] Semin Cancer Biol. 2008 Oct;18(5):349-55 [18467122.001]

(PMID = 21067513.001).

[ISSN] 1873-4251

[Journal-full-title] Current HIV research

[ISO-abbreviation] Curr. HIV Res.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / U01 CA066529; United States / NCI NIH HHS / CA / U01 CA066529; United States / NIMH NIH HHS / MH / U19 MH081835; United States / NIMH NIH HHS / MH / U19 MH081835

[Publication-type] Letter; Research Support, N.I.H., Extramural

[Publication-country] Netherlands

[Chemical-registry-number] 0 / nef Gene Products, Human Immunodeficiency Virus; 0 / nef protein, Human immunodeficiency virus 1

[Other-IDs] NLM/ NIHMS407811; NLM/ PMC3471533

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients].

[Transliterated title] Linfomas del tubo digestivo y glándulas anexas en pacientes con SIDA. Serie de casos.

BACKGROUND: Non-Hodgkin's lymphoma (NHL) is the second most common neoplasm among patients with AIDS.

One of the major clinical characteristics of AIDS-associated NHL is the high frequency of extra-nodal involvement, including the gastrointestinal tract, at initial presentation.

METHODS: From January 1997 to December 2004, 8 cases of NHL of the digestive tract and anexal glands (liver and parotid gland) were observed at the HIV/AIDS division of the Infectious Diseases FJ Muñiz Hospital from Buenos Aires, Argentina.

No patient was receiving highly active antiretroviral therapy (HAART) at lymphoma diagnosis.

The global incidence of AIDS-associated lymphomas (central nervous system lymphomas, non-Hodgkin lymphomas and Hodgkin lymphoma) during the time of study was 2,9% (54 cases); 17 patients (32%) had diagnosis of systemic NHL; 10 (58,8%) of them were extranodal at the onset of clinical symptoms and 8 (80%) involvement the digestive tract and anexal glands (parotid gland, cavum, esophagus, stomach, duodenum, the right colon in 2 patients and the liver), as primary NHL of high grade and "B" phenotype.

Primary duodenal lymphoma was the only Burkitt lymphoma of this serie and we detected the Epstein-Barr virus genome in the biopsy smears of this tumor and in the hepatic lymphoma.

CONCLUSION: NHL of the gastrointestinal tract is a severe complication of advanced HIV/AIDS disease.

[MeSH-major] Gastrointestinal Neoplasms / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Parotid Neoplasms / diagnosis

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - Liver Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17225446.001).

[ISSN] 0300-9033

[Journal-full-title] Acta gastroenterologica Latinoamericana

[ISO-abbreviation] Acta Gastroenterol. Latinoam.

[Language] spa

[Publication-type] English Abstract; Journal Article

[Publication-country] Argentina

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related lymphoma.

OBJECTIVE: To review the epidemiology, pathology, clinical features, prognostic factors, and treatment approaches of patients with AIDS-related lymphoma.

CONCLUSION: Aggressive B-cell lymphoma has become one of the more common of the initial AIDS-defining illnesses in the United States.

Median survival of affected patients has improved considerably with the use of highly active anti-retroviral therapy directed against human immunodeficiency virus, along with multi-agent chemotherapy, and outcome of such patients now approaches that of human immunodeficiency virus-negative patients with aggressive lymphoma.

IMPLICATIONS FOR NURSING PRACTICE: Oncology nurses must be knowledgeable of AIDS-related lymphoma to provide supportive care to this patient population.

[MeSH-major] Lymphoma, AIDS-Related

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16720230.001).

[ISSN] 0749-2081

[Journal-full-title] Seminars in oncology nursing

[ISO-abbreviation] Semin Oncol Nurs

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 72

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Multidrug resistance in AIDS-related lymphoma.

PURPOSE OF REVIEW: AIDS-related lymphoma has a decreased response rate and poorer prognosis to standard chemotherapy when compared with lymphoma in the non-HIV population.

In addition to the known HIV-related and lymphoma-related poor prognostic factors, this review discusses another factor, MDR-1 expression and its impact on response to therapy in patients with AIDS-related lymphoma.

RECENT FINDINGS: There is an increased incidence of de-novo MDR-1 expression in AIDS-related lymphoma compared with lymphoma in the non-HIV settings.

MDR-1 expression in AIDS-related lymphoma is associated with poor response to conventional combination chemotherapy.

Liposomal encapsulation of doxorubicin when substituted for doxorubicin in the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) seems to overcome P-glycoprotein-mediated drug resistance in AIDS-related lymphoma.

SUMMARY: The overexpression of MDR-1 gene product P-glycoprotein is an adverse prognostic factor in AIDS-related lymphoma.

Treatment with liposomal encapsulated doxorubicin seems to overcome the P-glycoprotein-related drug resistance.

This and other strategies to modulate MDR-1 should be further explored in order to improve success rates in the treatment of AIDS-related lymphoma.

[MeSH-major] Drug Resistance, Multiple, Viral / genetics. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / genetics

Genetic Alliance. consumer health - AIDS-HIV.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Pneumocystosis and HIV .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16093797.001).

[ISSN] 1040-8746

[Journal-full-title] Current opinion in oncology

[ISO-abbreviation] Curr Opin Oncol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; 0 / P-Glycoprotein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

[Number-of-references] 23

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Report of AIDS-related lymphoma in South Korea.

BACKGROUND: The prevalence of AIDS-related lymphoma (ARL) is increasing in South Korea.

RESULTS: The patients consisted of 20 males and 3 females at a median age of 40 (range, 20-72) on diagnosis of AIDS.

The histological diagnosis was aggressive B cell lymphoma in the majority, but rare T cell and NK/T cell lymphoma were also included.

Of 20 patients followed-up, nine were alive in remission, two alive in disease, one died of treatment related complication, four died of progressive lymphoma, four died of AIDS related causes.

The response to HARRT was evaluable in 13 patients based on CD4+ cell count and HIV viral load, among which nine (69.2%) responded.

As a substantial portion of the patients remains alive disease free, the impact of HAART on the clinical course of ARL needs further follow-up and evaluation.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / therapy

[MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Korea / epidemiology. Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / therapy. Lymphoma, T-Cell / epidemiology. Lymphoma, T-Cell / therapy. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18263652.001).

[ISSN] 1465-3621

[Journal-full-title] Japanese journal of clinical oncology

[ISO-abbreviation] Jpn. J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] Japan

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Decrease in Epstein-Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy.

Recent introduction of highly active antiretroviral therapy (HAART) is reported to have reduced the incidence of lymphoma among HIV-infected individuals.

A clinicopathological study was performed on 86 AIDS-related lymphoma patients who were treated in Tokyo area from 1987 to 2005.

The incidence of lymphoma detected by autopsy was 27% (53 cases/198 autopsies).

Diffuse large B cell lymphoma was the most predominant histological subtype throughout the period (78%).

Burkitt's lymphoma (BL) increased from 2% in the pre-HAART era (before end-1997) to 13% in the HAART era, whereas incidence of BL did not vary between HAART users and non-users.

Epstein-Barr virus (EBV)-positive lymphoma decreased from 88% in the pre-HAART era to 58% in the HAART era, but did not differ significantly between HAART users (73%) and non-users (74%).

Nodal involvement of lymphoma increased from 14% in the pre-HAART era to 50% in the HAART era; however, central nervous system involvement decreased from 62 to 38%.

Kaposi's sarcoma-associated herpesvirus infection was rare (4%) among all cases.

These data suggest that HAART might play a partial role in these changes, and the alteration in immunological backgrounds, such as EBV prevalence, is suggested as another leading cause of these changes in Japanese AIDS-related lymphoma.

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16697236.001).

[ISSN] 1286-4579

[Journal-full-title] Microbes and infection

[ISO-abbreviation] Microbes Infect.

[Language] ENG

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] France

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Response of AIDS-related plasmablastic lymphoma (PBL) to bortezomib.

: e19562 PBL are a group of highly aggressive neoplasms originally described in the oral cavity and jaws of HIV-infected patients.

An AIDS-defining illness, PBL comprises 2.6% of AIDS-related lymphomas.

A 42-year-old male with newly diagnosed AIDS presented with nausea, vomiting, bloody diarrhea and epigastric pain.

The WHO classifies PBL as a variant of diffuse large B-cell lymphoma.

However, studies of their immunophenotype and molecular histogenesis suggest that PBL are more closely related to plasma cell neoplasms.

Bortezomib is a proteasome inhibitor widely used in multiple myeloma and mantle cell lymphoma.

We chose bortezomib based on our patient's poor performance status and immune function, the desire to avoid combination chemotherapy, and translocations involving the immunoglobulin heavy chain gene locus (8;14) similar to those seen in multiple myeloma(4;14, 14;16) and mantle cell lymphoma(11;14).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961065.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related lymphoma (ARL): Efficacy of highly active anti retroviral therapy (HAART) on survival and prognostic factors in a general hospital in Peru.

METHODS: The clinical records of 2,502 HIV-infected patients seen in our institution from March 1997 to March 2008 were reviewed.

RESULTS: Forty-eight patients with HIV-associated lymphoma were identified.

From the 48 ARL identified 44 were non Hodgkin lymphoma (NHL) and 4 were Hodgkin lymphoma.

In a multivariate analysis, IPI score > 2, presence of B symptoms and no HAART previous ARL diagnosis were statistically associated to worse survival with p-values of 0.0001, 0.018 and 0.048 respectively.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27960996.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Human immunodeficiency virus/acquired immunodeficiency syndrome-related cancer in the pre- and post-highly active antiretroviral therapy era in a national cancer center of a resource-limited country: 1988 to 2007.

: e20550 Background: The introduction of the highly active antiretroviral therapy (HAART) has changed the clinical course of acquired immune deficiency syndrome (AIDS) related to cancer.

The goals were to describe the the characteristics of AIDS related to cancer before and after HAART in patients in a Hospital of a resource-limited country.

The number of invasive cervical cancer (CC) and AIDS-related lymphomas (ARLs) increased in the Post HAART era; the number on non-HIV/AIDS related to cancer has decreased.

CONCLUSIONS: The introduction of HAART has reduced the number of non-VIH/AIDS related cancer, but have increased the CC and LNH and improved the survival of patients.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961054.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV-associated peripheral T-cell lymphoma.

: e19551 Background: T-cell lymphomas (TCL) constitute 3% of all AIDS-related lymphomas.

Over the past 2 decades numerous case reports have documented the emergence of TCL among HIV-infected individuals.

These lymphomas comprise a diverse group of disease entities, including peripheral T-cell lymphomas (PTCL), which represent the most common subtype.

The aim of this study was to investigate the clinical and pathological features of HIV-associated PTCL.

METHODS: A MEDLINE search for cases of HIV-associated PTCL was conducted through December 2008.

Data regarding patient age, gender, HIV status (CD4 count, viral load, opportunistic infections), use of HAART, lymphoma features (B symptoms, stage, sites of involvement, immunophenotype, molecular studies), EBV coinfection, therapy, and outcome (survival, cause of death) were analyzed and reported descriptively.

Stage III and IV disease was found in 17 and 5 cases, respectively, accounting for 76% of the total cases.

Twenty-two patients (69%) died complicated by infections in 57% and lymphoma progression in 36% of cases.

CONCLUSIONS: HIV-associated PTCL tends to affect young male individuals with low CD4 counts.

Apart from marked immunosuppression, the poor prognosis of HIV-associated PTCL appears to be related to advanced stage at presentation, presence of B symptoms, elevated LDH levels, prominent extranodal disease, and poor response to CHOP chemotherapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961094.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV-associated anaplastic large cell lymphoma.

: e19563 Background: Anaplastic large cell lymphoma (ALCL) is a CD30+ T-cell lymphoma that is generally unrelated to EBV in the non-HIV setting.

Based upon anaplastic lymphoma kinase (ALK) expression, the new WHO classification provisionally distinguishes between ALK+ (favorable) and ALK- (unfavorable) ALCL.

The characteristics of ALCL, such as ALK expression and EBV coinfection, in individuals with HIV infection have not been adequately evaluated.

The aim of this study was to investigate these features in HIV-associated ALCL cases.

METHODS: A MEDLINE search for all cases of HIV-associated non-cutaneous ALCL was undertaken.

Data regarding patient age, gender, HIV status (CD4 count, viral load, opportunistic infections), HAART, lymphoma features (B symptoms, stage, sites of involvement, immunophenotype, ALK expression, molecular studies), EBV coinfection, therapy and outcome (survival, cause of death) were extracted and analyzed.

Median CD4+ count was 76 cells/mm3 and HIV viral load 416,500 copies/ml.

Many (78%) patients had stage IV disease and B symptoms were reported in 9 cases (50%).

Death was caused by either lymphoma progression (42%) or infection (58%).

CONCLUSIONS: HIV-associated non-cutaneous ALCL appears to affect younger individuals and is associated with EBV infection in a subset of cases.

Apart from marked immunosuppression, the poor prognosis of HIV-associated ALCL appears to be related to the absence of ALK expression, advanced stage at presentation with prominent extranodal disease, inadequate therapy including HAART, and poor response to CHOP.

Further research is needed to better understand and treat this unique HIV-associated lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961064.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The clinicopathological spectrum of HIV-associated lymphoma: Eleven-year-experience in a general hospital in Peru.

: e19561 Background: The clinicopathological spectrum of HIV-associated lymphomas in developing countries has not been clearly defined.

METHODS: This is a retrospective review of the clinical records of patients with diagnosis of HIV in our institution from March 1997 to March 2008.

RESULTS: Forty-eight patients with HIV-associated lymphoma were identified.

Forty-four cases (92%) were diagnosed with non-Hodgkin lymphoma (NHL) and 4 cases (8%) with Hodgkin lymphoma (HL).

From the 44 NHL cases, 40 cases (91%) were of B-cell origin; 23 cases (57.5%) had diffuse large B-cell, 9 cases (22.5%) had Burkitt, 3 cases (7.5%) had plasmablastic, 2 cases (5%) had primary CNS, 2 cases (5%) had MALT and 1 case (2.5%) had primary effusion lymphoma.

The remaining 4 cases (9%) were of T-cell origin; 3 cases (75%) had peripheral T-cell lymphoma NOS and 1 case (25%) was ALK-negative anaplastic large cell lymphoma.

Also a high proportion of T-cells lymphomas are found.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961062.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical and immunologic profile of AIDS-related lymphoma in the era of highly active antiretroviral therapy.

Despite the decrease in HIV-associated morbidity and mortality with the advent of highly active antiretroviral therapy (HAART), the incidence of AIDS-related lymphoma (ARL) has not decreased as significantly.

We used the Adult and Adolescent Spectrum of HIV-Related Diseases database of Public Health-Seattle and King County to determine incidences and trends among patients with ARL in Seattle/King County, WA.

There was also a significant increase in patients diagnosed with ARL at CD4+ counts > or = 200 cells/microL (3% vs. 21%) and a large decrease in median HIV-1 viral loads at ARL diagnosis (264,667 copies/mL vs. 35,500 copies/mL).

This changing profile of patients with ARL parallels larger changes seen among the general AIDS population in the HAART era.

[MeSH-major] Anti-Retroviral Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / immunology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17324334.001).

[ISSN] 1557-9190

[Journal-full-title] Clinical lymphoma & myeloma

[ISO-abbreviation] Clin Lymphoma Myeloma

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Anti-Retroviral Agents

[Number-of-references] 30

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma.

BACKGROUND: AIDS-related lymphoma contributes to significant morbidity and mortality among human immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral therapy (HAART).

We assessed the predictive role of cumulative HIV viremia and other risk factors in the development of AIDS-related non-Hodgkin lymphoma.

METHODS: Data from the Clinical Surveillance of HIV Disease (ClinSurv) study, an ongoing, observational, open cohort study of HIV-infected patients from different urban areas in Germany, were analyzed using a Cox proportional hazards model.

RESULTS: In the Cox model, which comprised 6022 patients and 27,812 patient-years of follow-up while patients were receiving HAART from 1999 through 2006, cumulative HIV viremia was found to be independently associated with the risk of lymphoma (hazard ratio, [HR], 1.67 [95% confidence interval {CI}, 1.27-2.20]) (P < .001]).

This association differed markedly between lymphoma subtypes.

Although the association was more pronounced for Burkitt-type lymphoma (HR, 3.45 [95% CI, 1.52-7.85]) (P = .003), there was no association between cumulative HIV viremia and the incidence of primary central nervous system lymphoma (HR, 1.00 [95% CI, 0.39-2.57]) (P = .997).

Other risk factors associated with an increased risk in a multivariable analysis included the latest CD4 T cell count as well as age per 10-year increment.

CONCLUSIONS: Cumulative HIV viremia is an independent and strong predictor of AIDS-related lymphoma among patients receiving HAART.

The influence of cumulative HIV viremia may differ between lymphoma subtypes.

[MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology. Viremia / complications

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] J Infect Dis. 2009 Jul 1;200(1):8-10 [19476436.001]

(PMID = 19476437.001).

[ISSN] 0022-1899

[Journal-full-title] The Journal of infectious diseases

[ISO-abbreviation] J. Infect. Dis.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Investigator] Kuehne A; Arastéh K; Kowol S; Bergmann F; Warnke M; Brockmeyer N; Mühlbächer N; Rockstroh J; Wasmuth J; Oette M; Blondin C; Esser S; Schenk-Westkamp P; Plettenberg A; Lorenzen T; Walther I; Adam A; Weitner L; Schewe K; Goey H; Fenske S; Buhk T; Gellerman H; Wassmuss K; Stoll M; Gerschmann S; Horst H; Fätkenheuer G; Kümmerle T; Gillor D; Bogner J; Sonntag B; Salzberger B; Fritzsche C

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.

OBJECTIVE: To assess the characteristics of combination antiretroviral therapy (cART) administered concomitantly with chemotherapy and to establish prognostic determinants of patients with AIDS-related non-Hodgkin's lymphoma.

METHODS: The study included 91 patients with AIDS-related non-Hodgkin's lymphoma from the Swiss HIV Cohort Study enrolled between January 1997 and October 2003, excluding lymphomas of the brain.

We extracted AIDS-related non-Hodgkin's lymphoma- and HIV-specific variables at the time of lymphoma diagnosis as well as treatment changes over time from charts and from the Swiss HIV Cohort Study database.

Thirty-five patients stopped chemotherapy prematurely (before the sixth cycle) usually due to disease progression; these patients had a shorter median survival than those who completed six or more cycles (14 versus 28 months).

Factors associated with overall survival were CD4+ T-cell count (<100 cells/microl) (hazard ratio [HR] 2.95 [95% confidence interval (CI) 1.53-5.67], hepatitis C seropositivity (HR 2.39 [95% CI 1.01-5.67]), the international prognostic index score (HR 1.98-3.62 across categories) and Burkitt histological subtypes (HR 2.56 [95% CI 1.13-5.78]).

The effect of cART interruptions on AIDS-related non-Hodgkin's lymphoma prognosis remains unclear, however, hepatitis C seropositivity emerged-as a predictor of death beyond the well-known international prognostic index score and CD4+ T-cell count.

[MeSH-major] Anti-HIV Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17926647.001).

[ISSN] 1359-6535

[Journal-full-title] Antiviral therapy

[ISO-abbreviation] Antivir. Ther. (Lond.)

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antineoplastic Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Management of AIDS-related lymphoma.

PURPOSE OF REVIEW: With the advent of highly active antiretroviral therapy, the epidemiology of AIDS-lymphoma has changed, and prognosis has improved.

Although the incidence of AIDS-lymphoma has decreased, the incidence of HIV-associated Hodgkin's lymphoma has increased; mechanisms for these changes in epidemiology will be discussed.

RECENT FINDINGS: Use of highly active antiretroviral therapy, either concomitantly or immediately after completion of chemotherapy, has resulted in rates of complete remission and survival that are similar to those in HIV-negative patients.

The use of rituximab, while initially controversial because of reports of increased risk of infectious death, is associated with improved outcome; the increased risk of infectious death has not been confirmed.

The infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin regimen is associated with excellent results.

High-dose chemotherapy with autologous stem cell transplant is associated with long-term, disease-free survival in approximately 50-80% of patients with relapsed/refractory AIDS-lymphoma.

Addition of rituximab is associated with improved response rates, without an increase in infections.

Infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin is associated with excellent results among patients with either diffuse large B cell lymphoma or Burkitt's lymphoma.

Optimal therapy for patients with HIV-Hodgkin's lymphoma has not yet been defined.

[MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19106654.001).

[ISSN] 1531-703X

[Journal-full-title] Current opinion in oncology

[ISO-abbreviation] Curr Opin Oncol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 48

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary pulmonary AIDS-related lymphoma.

Extranodal involvement is common in lymphomas associated with human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS).

However, primary pulmonary AIDS-related non-Hodgkin's lymphoma is very rare and only few reports were published in the medical literature.

Primary pulmonary lymphoma associated with AIDS is generally a high-grade B-cell non-Hodgkin lymphoma and Epstein-Barr virus is strongly associated with the pathogenesis of these tumors.

We report a patient with AIDS and primary pulmonary lymphoma which clinical presentation was a total atelectasis of the left lung.

[MeSH-major] Lung Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Pulmonary Atelectasis / etiology

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - Collapsed Lung.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16138208.001).

[ISSN] 0036-4665

[Journal-full-title] Revista do Instituto de Medicina Tropical de São Paulo

[ISO-abbreviation] Rev. Inst. Med. Trop. Sao Paulo

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Brazil

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Activation of mTORC1 signaling pathway in AIDS-related lymphomas.

Using immunohistochemistry with antibodies against the phosphoserine residues in both S6rp and 4E binding protein 1, we identified the activation of the mammalian target of rapamycin (mTORC)1 pathway in 29 cases of AIDS-related lymphoma.

These cases represented a diverse spectrum of histological types of non-Hodgkin lymphoma (24 cases) and classic Hodgkin lymphoma (five cases).

mTORC1 was also activated in the hyperplastic but not involuted follicles of HIV-associated lymphadenopathy in eight cases, supporting the notion that mTORC1 activation is a common feature of transformed lymphocytes irrespective of either their reactive or malignant phenotype.

We also found that in B-cell lines that represent diffuse large B-cell lymphoma, Burkitt lymphoma, Epstein-Barr virus-infected lymphocytes, and human herpesvirus 8-positive primary effusion lymphoma, inhibitors of Syk, MEK, and, seemingly, phosphoinositide 3 kinases suppressed mTORC1 activation, in particular when these inhibitors were used in combination.

These findings indicate that AIDS-related lymphoma and other histologically similar types of lymphomas that are derived from transformed B lymphocytes may display clinical responses to inhibitors that directly target mTORC1 or, possibly, upstream activators of the mTORC1 pathway.

Genetic Alliance. consumer health - AIDS-HIV.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Transpl Int. 2003 Mar;16(3):202-6 [12664217.001]

[Cites] EMBO J. 2002 Aug 1;21(15):4070-80 [12145207.001]

[Cites] J Biol Chem. 2003 Jun 13;278(24):21960-71 [12668683.001]

[Cites] J Biol Chem. 2003 Sep 26;278(39):37288-96 [12867426.001]

[Cites] Biochimie. 2003 Aug;85(8):763-9 [14585543.001]

[Cites] Transplantation. 2004 Mar 15;77(5):760-2 [15021843.001]

[Cites] Pediatr Transplant. 2004 Jun;8(3):243-8 [15176961.001]

[Cites] J Biol Chem. 1991 Aug 15;266(23):14846-9 [1869521.001]

[Cites] J Biol Chem. 1992 Apr 25;267(12):8613-9 [1569106.001]

[Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9107-11 [1409610.001]

[Cites] J Biol Chem. 1993 Jul 25;268(21):15900-5 [8340414.001]

[Cites] J Biol Chem. 1993 Nov 15;268(32):24442-8 [8226994.001]

[Cites] J Biol Chem. 1994 Feb 25;269(8):5918-25 [8119935.001]

[Cites] J Immunol. 1994 Jun 1;152(11):5429-37 [8189062.001]

[Cites] EMBO J. 1996 Oct 1;15(19):5256-67 [8895571.001]

[Cites] Immunol Lett. 1999 Jun 1;68(2-3):301-9 [10424436.001]

[Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]

[Cites] J Virol. 2005 May;79(9):5499-506 [15827164.001]

[Cites] Cell. 2005 Apr 22;121(2):179-93 [15851026.001]

[Cites] J Biol Chem. 2005 May 20;280(20):19937-47 [15760907.001]

[Cites] Nephrol Dial Transplant. 2005 Aug;20(8):1748-51 [15919698.001]

[Cites] Cancer Res. 2005 Sep 1;65(17):7800-8 [16140948.001]

[Cites] Microsc Res Tech. 2005 Nov;68(3-4):168-75 [16276515.001]

[Cites] Cell Res. 2005 Nov-Dec;15(11-12):947-52 [16354573.001]

[Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]

[Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]

[Cites] Br J Cancer. 2006 Jan 30;94(2):195-9 [16404421.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5466-71 [16567633.001]

[Cites] Am J Kidney Dis. 2006 May;47(5):e67-72 [16632009.001]

[Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]

[Cites] Cancer Cell. 2006 Aug;10(2):133-43 [16904612.001]

[Cites] Nat Rev Cancer. 2006 Sep;6(9):729-34 [16915295.001]

[Cites] J Biol Chem. 2006 Sep 15;281(37):26904-13 [16816403.001]

[Cites] Oncogene. 2006 Oct 16;25(48):6347-60 [17041621.001]

[Cites] Blood. 2006 Dec 15;108(13):4156-62 [16912221.001]

[Cites] Lab Invest. 2007 Jan;87(1):29-39 [17075574.001]

[Cites] Transplant Proc. 2007 May;39(4):1267-71 [17524950.001]

[Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]

[Cites] Blood. 2007 Jul 1;110(1):278-86 [17363738.001]

[Cites] Transplant Proc. 2007 Jul-Aug;39(6):2036-7 [17692685.001]

[Cites] Oncogene. 2007 Aug 16;26(38):5606-14 [17353907.001]

[Cites] Blood. 2008 Feb 15;111(4):2181-9 [18025151.001]

[Cites] Transpl Int. 2008 Jun;21(6):605-8 [18282244.001]

[Cites] Blood. 2007 Mar 1;109(5):2165-73 [17082322.001]

[Cites] Biochem J. 1999 Dec 1;344 Pt 2:427-31 [10567225.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4285-90 [10759564.001]

[Cites] Cancer Res. 2000 Jul 1;60(13):3504-13 [10910062.001]

[Cites] Transplantation. 2003 May 27;75(10):1710-7 [12777861.001]

(PMID = 19608873.001).

[ISSN] 1525-2191

[Journal-full-title] The American journal of pathology

[ISO-abbreviation] Am. J. Pathol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA089194; United States / NIDCR NIH HHS / DE / R01 DE017337; United States / NCI NIH HHS / CA / R01-CA89194; United States / NIDCR NIH HHS / DE / R01-DE-017337

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Phospho-Specific; 0 / Multiprotein Complexes; 0 / Proteins; 0 / Transcription Factors; 0 / mechanistic target of rapamycin complex 1; 17885-08-4 / Phosphoserine; EC 2.7.1.1 / TOR Serine-Threonine Kinases

[Other-IDs] NLM/ PMC2716976

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Small bowel lymphoma detected by MiroCam capsule endoscope in a patient with acquired immune deficiency syndrome].

Human immunodeficiency virus (HIV) infection is a risk factor for developing non-Hodgkin's lymphoma.

Most acquired immune deficiency syndrome (AIDS)-related lymphomas are high-grade B cell non-Hodgkin's lymphomas.

The use of highly active antiretroviral therapy has reduced the incidence of AIDS-related lymphoma.

There have been 7 reports of AIDS-related extra-nodal lymphoma in Korea.

We report a case of AIDS-related lymphoma detected by MiroCam capsule endoscopy.

[MeSH-major] Acquired Immunodeficiency Syndrome / complications. Capsule Endoscopes. Jejunal Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis

[MeSH-minor] Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / virology. Humans. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Tomography, X-Ray Computed

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - Intestinal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19077490.001).

[ISSN] 1598-9992

[Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

[ISO-abbreviation] Korean J Gastroenterol

[Language] kor

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Korea (South)

[Chemical-registry-number] 0 / Anti-HIV Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma.

Human immunodeficiency virus-infected patients are at an increased risk for developing both Hodgkin and non-Hodgkin lymphoma when compared with the general population.

With the remarkable decrease in the incidence of opportunistic infections since the availability of highly active antiretroviral therapy (HAART), acquired immune deficiency syndrome-related lymphoma (ARL) is now the second most common cancer associated with human immunodeficiency virus after Kaposi sarcoma.

Over the last few years, advances in our understanding of the molecular biology of this heterogeneous group of lymphomas have led to the adoption of new classification systems.

Apart from the contribution of HAART, this improvement in prognosis can also be attributed to new initiatives in treatment of these patients, such as the use of effective infusional regimens, the feasibility of high-dose therapy with peripheral stem cell rescue for relapsed or refractory disease, and better supportive care.

Nonetheless, several controversial issues persist, including the optimal timing of HAART with combination chemotherapy, the role of rituximab when incorporated into treatment regimens, and the optimal therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma.

[MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / physiopathology

[MeSH-minor] AIDS-Related Opportunistic Infections. Drug Administration Schedule. Humans. Incidence. Peripheral Blood Stem Cell Transplantation. Prevalence. Prognosis

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16020424.001).

[ISSN] 0007-9235

[Journal-full-title] CA: a cancer journal for clinicians

[ISO-abbreviation] CA Cancer J Clin

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 52

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genomic imbalances in AIDS-related lymphomas: relation with tumoral Epstein-Barr virus status.

BACKGROUND: The pathologic heterogeneity of AIDS related lymphomas (ARL) reflects several pathogenic mechanisms: chronic antigenic stimulation, Epstein-Barr virus (EBV) infection, and genomic abnormalities.

Genetic abnormalities, known to play a major role in lymphomas of non-immunocompromised patients, are not well characterized in ARL.

DNA-CNC tended to be more frequent in EBV-positive lymphomas with latency type II/III than in EBV-positive latency I or EBV-negative lymphomas.

Most chromosomal regions affected in HIV-related lymphoma were similar to those already reported in HIV-negative lymphomas.

The results suggested an inverse relationship between EBV infection (latency II/III), associated with deep acquired immune suppression, and the number of chromosomal alterations which may be explained by a direct role of viral proteins in lymphomagenesis by activation of signalling pathways without needing several genomic alterations.

[MeSH-major] Epstein-Barr Virus Infections / genetics. Lymphoma, AIDS-Related / genetics

[MeSH-minor] Adult. Aged. Burkitt Lymphoma / complications. Burkitt Lymphoma / genetics. Burkitt Lymphoma / immunology. CD4 Lymphocyte Count. CD4-Positive T-Lymphocytes / immunology. Chromosome Aberrations. Chromosomes, Human / genetics. Clone Cells / immunology. DNA, Viral / genetics. Female. Genes, Viral / genetics. Genes, Viral / immunology. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, T-Cell, Peripheral / complications. Lymphoma, T-Cell, Peripheral / genetics. Lymphoma, T-Cell, Peripheral / immunology. Male. Middle Aged. Nucleic Acid Hybridization / methods

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17117014.001).

[ISSN] 0269-9370

[Journal-full-title] AIDS (London, England)

[ISO-abbreviation] AIDS

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / DNA, Viral

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] EBV and HIV-Related Lymphoma.

HIV-associated lymphoproliferative disorders represent a heterogeneous group of diseases, arising in the presence of HIV-associated immunodeficiency.

The overall prevalence of HIV-associated lymphoma is significantly higher compared to that of the general population and it continues to be relevant even after the wide availability of highly active antiretroviral therapy (HAART) (1).

Moreover, they still represent one of the most frequent cause of death in HIV-infected patients.

Epstein-Barr virus (EBV), a γ-Herpesviruses, is involved in human lymphomagenesis, particularly in HIV immunocompromised patients.

It has been largely implicated in the development of B-cell lymphoproliferative disorders as Burkitt lymphoma (BL), Hodgkin disease (HD), systemic non Hodgkin lymphoma (NHL), primary central nervous system lymphoma (PCNSL), nasopharyngeal carcinoma (NC).

Virus-associated lymphomas are becoming of significant concern for the mortality of long-lived HIV immunocompromised patients, and therefore, research of advanced strategies for AIDS-related lymphomas is an important field in cancer chemotherapy.

Detailed understanding of the EBV lifecycle and related cancers at the molecular level is required for novel strategies of molecular-targeted cancer chemotherapy The linkage of HIV-related lymphoma with EBV infection of the tumor clone has several pathogenetic, prognostic and possibly therapeutic implications which are reviewed herein.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Semin Oncol. 1999 Jun;26(3):346-56 [10375091.001]

[Cites] Blood. 2001 Jul 1;98(1):146-55 [11418474.001]

[Cites] Blood. 2001 Oct 15;98(8):2339-44 [11588028.001]

[Cites] J Exp Med. 2001 Dec 17;194(12):1731-41 [11748275.001]

[Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]

[Cites] Nat Med. 2002 Apr;8(4):319-23 [11927927.001]

[Cites] AIDS. 2002 May 24;16(8):1195-6 [12004285.001]

[Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]

[Cites] Blood. 2003 Mar 15;101(6):2321-7 [12406882.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15572-7 [12434018.001]

[Cites] Lancet. 2003 Jan 18;361(9353):217-23 [12547545.001]

[Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]

[Cites] Cancer Res. 2003 Jun 1;63(11):2982-9 [12782607.001]

[Cites] Blood. 2003 Dec 1;102(12):4166-78 [12907455.001]

[Cites] Oncogene. 2003 Aug 11;22(33):5108-21 [12910248.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]

[Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]

[Cites] Ann Oncol. 2003 Oct;14(10):1562-9 [14504059.001]

[Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]

[Cites] Clin Cancer Res. 2004 Feb 1;10(3):803-21 [14871955.001]

[Cites] Am J Clin Pathol. 2004 May;121(5):727-38 [15151213.001]

[Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]

[Cites] J Pathol. 2008 Sep;216(1):83-92 [18566961.001]

[Cites] Am J Hematol. 2008 Oct;83(10):763-4 [18756546.001]

[Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]

[Cites] J Exp Med. 1986 Dec 1;164(6):2049-60 [3491176.001]

[Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]

[Cites] Oncogene. 1995 Feb 2;10(3):549-60 [7845680.001]

[Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]

[Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]

[Cites] J Clin Oncol. 1993 Sep;11(9):1674-81 [8394878.001]

[Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]

[Cites] Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7635-9 [1652756.001]

[Cites] Lancet. 1991 Oct 19;338(8773):969-73 [1681341.001]

[Cites] J Exp Med. 1991 Jan 1;173(1):147-58 [1845872.001]

[Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]

[Cites] Am J Hematol. 1989 Nov;32(3):200-4 [2816914.001]

[Cites] Cell. 1985 Dec;43(3 Pt 2):831-40 [3000618.001]

[Cites] J Clin Oncol. 1995 Jul;13(7):1758-67 [7541452.001]

[Cites] Am J Pathol. 1993 Oct;143(4):1072-85 [8214003.001]

[Cites] J Virol. 1996 Feb;70(2):1143-53 [8551575.001]

[Cites] AIDS. 1996 Aug;10(9):951-8 [8853727.001]

[Cites] Curr Opin Oncol. 1996 Sep;8(5):373-6 [9026061.001]

[Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):16-23 [9892104.001]

[Cites] BMJ. 1999 Jul 3;319(7201):23-4 [10390454.001]

[Cites] Neurology. 2000 Feb 22;54(4):993-7 [10691003.001]

[Cites] Arch Pathol Lab Med. 2001 Feb;125(2):282-5 [11175653.001]

[Cites] AJNR Am J Neuroradiol. 1997 Mar;18(3):563-72 [9090424.001]

[Cites] J Clin Invest. 1997 Apr 1;99(7):1525-33 [9119996.001]

[Cites] Am J Surg Pathol. 1997 Jun;21(6):719-24 [9199651.001]

[Cites] J Clin Pathol. 1997 Nov;50(11):911-8 [9462239.001]

[Cites] Am J Pathol. 1998 Mar;152(3):623-30 [9502401.001]

[Cites] Haematologica. 1998 Jan;83(1):87-9 [9542326.001]

[Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]

[Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]

[Cites] Am J Hematol. 2004 Nov;77(3):291-5 [15495247.001]

[Cites] AIDS. 2002 Oct 18;16(15):2001-11 [12370498.001]

[Cites] AIDS. 2003 Jan 3;17(1):81-7 [12478072.001]

[Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]

[Cites] J Clin Pathol. 2003 Mar;56(3):188-92 [12610094.001]

[Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]

[Cites] Am J Hematol. 2003 Jul;73(3):143-8 [12827649.001]

[Cites] Cancer. 2003 Jul 15;98(2):300-9 [12872349.001]

[Cites] Blood. 1992 Apr 1;79(7):1768-74 [1373087.001]

[Cites] Am J Hematol. 2004 May;76(1):88-91 [15114607.001]

[Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]

[Cites] Neurology. 1997 Mar;48(3):687-94 [9065549.001]

[Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]

[Cites] Presse Med. 2004 Dec 4;33(21):1487-92 [15637794.001]

[Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]

[Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]

[Cites] Blood. 2005 Dec 15;106(13):4339-44 [16076866.001]

[Cites] Clin Infect Dis. 2005 Oct 15;41(8):e76-9 [16163622.001]

[Cites] Hematol Oncol. 2005 Jun;23(2):61-7 [16216037.001]

[Cites] J Pathol. 2006 Jan;208(2):176-86 [16362996.001]

[Cites] J Gen Virol. 2006 May;87(Pt 5):1047-74 [16603506.001]

[Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]

[Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]

[Cites] Hum Pathol. 2006 Sep;37(9):1233-6 [16938530.001]

[Cites] Blood. 2007 Mar 1;109(5):2165-73 [17082322.001]

[Cites] Blood. 2007 Mar 15;109(6):2597-603 [17148591.001]

[Cites] Oncogene. 2007 Aug 2;26(35):5115-23 [17325665.001]

[Cites] Adv Anat Pathol. 2007 May;14(3):189-94 [17452815.001]

[Cites] Blood. 2007 Nov 15;110(10):3715-21 [17682125.001]

[Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]

[Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]

[Cites] Blood. 2008 Apr 1;111(7):3813-20 [18230756.001]

[Cites] Blood Rev. 2008 Sep;22(5):261-81 [18456377.001]

[Cites] Am J Pathol. 2008 Jul;173(1):195-204 [18502823.001]

[Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1447-52 [9037073.001]

[Cites] AIDS. 1997 Oct;11(12):1522-3 [9342077.001]

[Cites] Cancer. 1998 Feb 15;82(4):766-74 [9477111.001]

[Cites] J Natl Cancer Inst. 1998 Mar 4;90(5):364-9 [9498486.001]

[Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]

[Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11963-8 [9751773.001]

[Cites] Immunity. 1998 Sep;9(3):405-11 [9768760.001]

[Cites] Am J Pathol. 1998 Nov;153(5):1609-14 [9811353.001]

[Cites] AIDS. 2001 Nov 9;15(16):2119-27 [11684931.001]

[Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]

[Cites] Dermatology. 2004;208(3):287-90 [15118393.001]

[Cites] Clin Infect Dis. 2004 Jun 1;38(11):1629-32 [15156453.001]

[Cites] Cancer. 2004 Jun 15;100(12):2627-36 [15197806.001]

[Cites] J Clin Oncol. 2004 Oct 15;22(20):4227-8 [15483034.001]

[Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]

[Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]

[Cites] J Clin Oncol. 1999 Feb;17(2):554-60 [10080599.001]

[Cites] Arch Pathol Lab Med. 1999 Mar;123(3):257-60 [10086517.001]

[Cites] Blood. 1999 Apr 1;93(7):2319-26 [10090942.001]

[Cites] Crit Rev Oncog. 1998;9(3-4):199-208 [10201628.001]

(PMID = 21416008.001).

[ISSN] 2035-3006

[Journal-full-title] Mediterranean journal of hematology and infectious diseases

[ISO-abbreviation] Mediterr J Hematol Infect Dis

[Language] eng

[Publication-type] Journal Article

[Publication-country] Italy

[Other-IDs] NLM/ PMC3033170

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors.

After the introduction of highly active antiretroviral therapy (HAART), intensive treatment, including high-dose therapy (HDT) and peripheral blood stem cell transplantation (PBSCT), has become feasible in HIV-positive patients with Hodgkin (HL) and non-Hodgkin (NHL) lymphoma.

Herein, we report the long-term results, on an intention-to-treat basis, of a prospective study on HDT and PBSCT in 50 HIV-positive HAART-responding patients with refractory/relapsed lymphoma.

After debulking therapy, 2 patients had early toxic deaths, 10 had chemoresistant disease, 6 failed stem cell mobilization, 1 refused collection, and 4 progressed soon after PBSC harvest.

Twenty-one patients are alive and disease-free after a median follow-up of 44 months (OS, 74.6%; PFS, 75.9%).

Only lymphoma response significantly affected OS after transplantation.

In multivariate analyses both lymphoma stage and low CD4 count negatively influenced the possibility to receive transplant.

PBSCT is a highly effective salvage treatment for chemosensitive AIDS-related lymphoma.

It seems rational to explore its use earlier during the course of lymphoma to increase the proportion of patients who can actually receive transplant.

[MeSH-major] Acquired Immunodeficiency Syndrome / therapy. Antiretroviral Therapy, Highly Active. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation

[MeSH-minor] Adult. CD4 Lymphocyte Count. Disease-Free Survival. Female. Follow-Up Studies. Humans. Italy. Male. Middle Aged. Salvage Therapy / methods. Survival Rate. Transplantation, Autologous

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

MedlinePlus Health Information. consumer health - Hodgkin Disease.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Blood. 2009 Aug 13;114(7):1284-5 [19679696.001]

(PMID = 19451551.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Successful autologous stem cell transplantation in a severely immunocompromised patient with relapsed AIDS-related B-cell lymphoma.

There is now evidence that the tolerability and response to systemic chemotherapy in HIV-infected patients with AIDS-related lymphoma (ARL) is significantly improved by highly active antiretroviral therapy.

Here we report an severely immunocompromised AIDS patient with recurrent ARL who was successfully treated with autologous stem cell transplantation (ASCT).

We also review the current literature of ASCT in HIV-infected patients.

[MeSH-major] B-Lymphocytes / pathology. Hematopoietic Stem Cell Transplantation. Immunocompromised Host. Lymphoma, AIDS-Related / therapy

[MeSH-minor] Adult. HIV Infections / complications. HIV Infections / pathology. Humans. Male. Transplantation, Autologous. Treatment Outcome

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16504964.001).

[ISSN] 0949-2321

[Journal-full-title] European journal of medical research

[ISO-abbreviation] Eur. J. Med. Res.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Therapy insight: AIDS-related malignancies--the influence of antiviral therapy on pathogenesis and management.

Patients with HIV infection are at an increased risk of a number of malignancies, including Kaposi's sarcoma (KS) and certain B-cell lymphomas.

Most of these tumors are caused by oncogenic DNA viruses, including KS-associated herpesvirus and Epstein-Barr virus.

HIV contributes to the development of these tumors through several mechanisms, including immunodeficiency, immunodysregulation, and the effects of HIV proteins such as Tat.

The development of highly active antiretroviral therapy (HAART) has reduced the incidence of many HIV-associated tumors and has generally improved their responsiveness to therapy.

However, the number of people living with AIDS is increasing, and it is possible that the number of AIDS-associated malignancies will rise and the pattern of tumors will change as more people live longer with HIV infection.

By contrast, the goal of AIDS-related lymphoma therapy in most cases is the attainment of a complete response with curative intent, and the benefits of administering HAART during therapy must be weighed against possible disadvantages.

The past decade has seen substantial improvements in the treatment of AIDS-related lymphoma, which is attributed partially to a shift in tumor type and more effective regimens.

There is currently an interest in developing new therapies for HIV-associated malignancies, based on viral, vascular or other pathogenesis-based targets.

[MeSH-major] Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / complications. Neoplasms / drug therapy. Neoplasms / virology

[MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / physiopathology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / physiopathology. Sarcoma, Kaposi / virology

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16130937.001).

[ISSN] 1743-4254

[Journal-full-title] Nature clinical practice. Oncology

[ISO-abbreviation] Nat Clin Pract Oncol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 73

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Noninfectious pulmonary complications of HIV/AIDS.

PURPOSE OF REVIEW: This article reviews recent findings on noninfectious pulmonary complications of HIV/AIDS, with a focus on HIV/AIDS-related lung malignancies and pulmonary hypertension, and discusses their incidence in the highly active antiretroviral therapy (HAART) era.

RECENT FINDINGS: Noninfectious pulmonary complications of HIV/AIDS are now recognized as important contributors to morbidity and mortality in HIV-infected patients.

This is especially the case for HIV-related lung cancer and other non-AIDS-defining malignancies, which are now being diagnosed with increased frequency in HIV-infected patients.

The incidence of Kaposi sarcoma and AIDS-related lymphoma has decreased in the HAART era, but compared with the general population, the risk of these malignancies and pulmonary hypertension is still very high in HIV-infected patients.

Concurrent use of HAART and chemotherapy improves prognosis and survival of patients with AIDS-related lymphoma.

For patients with HIV-related pulmonary hypertension, some studies show no beneficial effect of HAART whereas other reports show that HAART improves patient survival and response to antihypertensive treatment.

SUMMARY: The beneficial effect of HAART and improved immune response on the treatment of Kaposi sarcoma and AIDS-related lymphoma suggests that HIV or viral-induced immunosuppression plays an important role in the development of these malignancies.

Evidence from current studies suggests that HAART does not protect against HIV-related lung cancer.

The full impact of HAART on HIV pulmonary hypertension remains to be determined.

[MeSH-major] Acquired Immunodeficiency Syndrome / epidemiology. Hypertension, Pulmonary / epidemiology. Lung Neoplasms / epidemiology. Lymphoma, AIDS-Related / epidemiology. Sarcoma, Kaposi / epidemiology

[MeSH-minor] Antiretroviral Therapy, Highly Active. Comorbidity. Female. HIV Infections / diagnosis. HIV Infections / drug therapy. HIV Infections / epidemiology. Humans. Incidence. Male. Prognosis. Severity of Illness Index. Survival Analysis

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

MedlinePlus Health Information. consumer health - Lung Cancer.

MedlinePlus Health Information. consumer health - Pulmonary Hypertension.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15818181.001).

[ISSN] 1070-5287

[Journal-full-title] Current opinion in pulmonary medicine

[ISO-abbreviation] Curr Opin Pulm Med

[Language] eng

[Grant] United States / NIMH NIH HHS / MH / 1KO1MH068214-1

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review

[Publication-country] United States

[Number-of-references] 54

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related lymphoproliferative disease.

Not long after the recognition of HIV as the causative agent of AIDS, it was evident that individuals infected with HIV developed lymphoma at a greater rate than the population at large.

Approximately two thirds of AIDS-related lymphoma (ARL) cases are categorized as diffuse large B-cell type, with Burkitt lymphomas comprising 25% and other histologies a much smaller proportion.

Typically, these individuals have presented with advanced extranodal disease and CD4+ lymphocyte counts of less than 200/mm3.

Coinfection with other viruses such as Epstein-Barr virus and Kaposi sarcoma-associated herpesvirus have led to the genesis of previously rare or unrecognized lymphoma subtypes such as plasmablastic and primary effusion lymphomas.

Significant progress has been made in the understanding and management of ARL but outcomes still remain inferior compared to those achieved in HIV- individuals.

[MeSH-major] Lymphoma, AIDS-Related / therapy

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16099881.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 100

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Circulating serum free light chains as predictive markers of AIDS-related lymphoma.

PURPOSE HIV-infected persons have an elevated risk of developing non-Hodgkin's lymphoma (NHL); this risk remains increased in the era of effective HIV therapy.

We evaluated serum immunoglobulin (Ig) proteins as predictors of NHL risk among HIV-infected individuals.

PATIENTS AND METHODS By using three cohorts of HIV-infected persons (from 1982 to 2005), we identified 66 individuals who developed NHL and 225 matched (by cohort, sex, ethnicity, age, and CD4 count), HIV-infected, lymphoma-free controls who had available stored prediagnostic blood samples.

M proteins were detected in only two patients with NHL (3%) and in nine controls (4%), and they were not significantly associated with NHL risk.

CONCLUSION Elevated FLCs may represent sensitive markers of polyclonal B-cell activation and dysfunction and could be useful for identifying HIV-infected persons at increased NHL risk.

[MeSH-major] Biomarkers, Tumor / blood. Immunoglobulin kappa-Chains / blood. Immunoglobulin lambda-Chains / blood. Lymphoma, AIDS-Related / immunology

Genetic Alliance. consumer health - AIDS-HIV.

COS Scholar Universe. author profiles.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Rev Immunol. 2009 Apr;9(4):235-45 [19319142.001]

[Cites] Ann Rheum Dis. 2009 Jan;68(1):89-93 [18375535.001]

[Cites] Blood. 2009 May 28;113(22):5412-7 [19179464.001]

[Cites] J Acquir Immune Defic Syndr. 2010 May 1;54(1):78-84 [20418723.001]

[Cites] AIDS. 2000 Jan 28;14(2):133-40 [10708283.001]

[Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]

[Cites] Blood. 2001 May 1;97(9):2900-2 [11313287.001]

[Cites] N Engl J Med. 2002 Feb 21;346(8):564-9 [11856795.001]

[Cites] Clin Chem. 2002 Sep;48(9):1437-44 [12194920.001]

[Cites] Blood. 2003 Nov 15;102(10):3759-64 [12881316.001]

[Cites] Curr HIV Res. 2004 Jan;2(1):11-21 [15053337.001]

[Cites] AIDS Read. 2004 Jul;14(7):372-4, 377-9 [15282866.001]

[Cites] N Engl J Med. 2004 Oct 7;351(15):1548-63 [15470219.001]

[Cites] N Engl J Med. 1983 Aug 25;309(8):453-8 [6224088.001]

[Cites] JAMA. 1987 Jan 16;257(3):331-4 [3491911.001]

[Cites] Clin Chem. 1987 Sep;33(9):1697-8 [3621592.001]

[Cites] Clin Chem. 1989 Feb;35(2):338-9 [2914402.001]

[Cites] N Engl J Med. 1989 Oct 26;321(17):1141-8 [2477702.001]

[Cites] Br J Haematol. 1993 May;84(1):151-5 [8101720.001]

[Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]

[Cites] Leukemia. 1997 Dec;11(12):2150-6 [9447834.001]

[Cites] Int J Cancer. 2005 Jun 10;115(2):296-300 [15688390.001]

[Cites] Blood. 2005 Aug 1;106(3):812-7 [15855274.001]

[Cites] Haemophilia. 2005 Sep;11(5):516-28 [16128897.001]

[Cites] N Engl J Med. 2006 Mar 30;354(13):1362-9 [16571879.001]

[Cites] Tumour Biol. 2006;27(4):187-94 [16651853.001]

[Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]

[Cites] Curr Opin Oncol. 2006 Sep;18(5):444-8 [16894291.001]

[Cites] Clin Infect Dis. 2006 Nov 1;43(9):1198-205 [17029142.001]

[Cites] Ann Rheum Dis. 2007 Jan;66(1):23-7 [16569685.001]

[Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]

[Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]

[Cites] JAMA. 2008 Aug 6;300(5):555-70 [18677028.001]

[Cites] N Engl J Med. 2009 Apr 30;360(18):1815-26 [19339714.001]

(PMID = 20048176.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Grant] United States / Intramural NIH HHS / / Z01 CP010150-08; United States / NCI NIH HHS / CA / P01 CA062242; United States / NCI NIH HHS / CA / CA 107476; United States / NCI NIH HHS / CA / R01 CA107476; United States / NCI NIH HHS / CA / CA 62242

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains

[Other-IDs] NLM/ PMC2834393

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART).

Non-Hodgkin's lymphoma is an AIDS-defining disease.

We collected data of 214 cases of AIDS-related Lymphoma (ARL) treated at our centre from January 1984 until May 2003 and analysed them using the Kaplan-Meier-, log rank- and Cox proportional hazard-model.

The incidence of AIDS-related primary CNS lymphomas (PCNSL) took a comparable, yet more pronounced development.

Using the univariate Kaplan-Meier analysis prolonged survival was significantly associated with the achievement of a complete remission as well as with a favourable virological response to HAART.

[MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / epidemiology

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15621803.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antiviral Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma.

HIV infection is associated with a much higher risk for the development of non-Hodgkin lymphoma (AIDS-NHL).

The principal causes of lymphomagenesis in HIV-infected individuals are thought to be the loss of immune function seen in HIV infection, which results in the loss of immunoregulation of Epstein-Barr virus-infected B cells, as well as HIV infection-associated immune dysregulation, including chronic B-cell activation.

In this review, we discuss recent reports that further support the importance of these factors, and we highlight emerging evidence of different mechanisms that potentially drive lymphomagenesis in HIV-infected individuals.

[MeSH-major] AIDS-Related Opportunistic Infections / immunology. Acquired Immunodeficiency Syndrome / immunology. B-Lymphocytes / immunology. Epstein-Barr Virus Infections / immunology. HIV / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / immunology

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Semin Oncol. 2000 Aug;27(4):431-41 [10950370.001]

[Cites] Immunity. 2000 Oct;13(4):485-95 [11070167.001]

[Cites] J Virol. 2001 Jul;75(13):6173-82 [11390619.001]

[Cites] AIDS. 2001 May 25;15(8):957-64 [11399977.001]

[Cites] Blood. 2001 Jul 1;98(1):146-55 [11418474.001]

[Cites] Eur J Immunol. 2001 May;31(5):1544-9 [11465112.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4730-5 [12665622.001]

[Cites] Tumour Biol. 2003 Mar-Apr;24(2):82-93 [12853703.001]

[Cites] Nat Rev Immunol. 2003 Aug;3(8):609-20 [12974476.001]

[Cites] Clin Immunol. 2003 Nov;109(2):119-29 [14597210.001]

[Cites] J Immunol. 2003 Nov 15;171(10):5215-24 [14607922.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4262-7 [14999097.001]

[Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]

[Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(11):3456-60 [6222380.001]

[Cites] Science. 1986 Sep 5;233(4768):1084-6 [3016902.001]

[Cites] J Immunol. 1987 Jun 1;138(11):3720-4 [2953790.001]

[Cites] Immunol Today. 1989 May;10(5):153-7 [2525911.001]

[Cites] J Exp Med. 1989 Dec 1;170(6):2081-95 [2531194.001]

[Cites] Immunology. 1989 Dec;68(4):526-31 [2481643.001]

[Cites] AIDS. 1992 Oct;6(10):1105-16 [1466841.001]

[Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]

[Cites] J Clin Oncol. 1993 Jun;11(6):1099-107 [8099121.001]

[Cites] Blood. 1993 Dec 1;82(11):3430-6 [8241510.001]

[Cites] Eur J Immunol. 1994 Aug;24(8):1869-73 [8056045.001]

[Cites] Immunol Today. 1994 Sep;15(9):418-22 [7524519.001]

[Cites] J Immunol. 1995 Mar 15;154(6):2533-44 [7533177.001]

[Cites] Blood. 1995 Apr 1;85(7):1843-9 [7703491.001]

[Cites] Mol Med. 1995 Jul;1(5):495-505 [8529116.001]

[Cites] Ann Intern Med. 1997 Sep 15;127(6):423-8 [9312998.001]

[Cites] Leuk Lymphoma. 1998 Jul;30(3-4):257-67 [9713958.001]

[Cites] Clin Immunol. 1999 Feb;90(2):157-64 [10080826.001]

[Cites] Blood. 1999 Jul 1;94(1):275-82 [10381523.001]

[Cites] Clin Immunol. 1999 Sep;92(3):293-9 [10479534.001]

[Cites] Clin Immunol. 1999 Nov;93(2):114-23 [10527687.001]

[Cites] J Immunol. 2005 Jun 15;174(12):7912-9 [15944297.001]

[Cites] Blood. 2005 Aug 1;106(3):1031-6 [15840698.001]

[Cites] AIDS. 2005 Oct 14;19(15):1711-2 [16184051.001]

[Cites] J Interferon Cytokine Res. 2005 Nov;25(11):702-6 [16318584.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18093-8 [16330748.001]

[Cites] J Immunol. 2006 Apr 1;176(7):3931-41 [16547227.001]

[Cites] RNA. 2006 May;12(5):733-50 [16540699.001]

[Cites] Tumour Biol. 2006;27(4):187-94 [16651853.001]

[Cites] PLoS Pathog. 2006 Mar;2(3):e23 [16557291.001]

[Cites] Mol Immunol. 2007 Jan;44(4):494-505 [16574227.001]

[Cites] Mol Immunol. 2007 Feb;44(5):934-42 [16730063.001]

[Cites] Blood. 2006 Dec 1;108(12):3859-64 [16882707.001]

[Cites] Ann Rheum Dis. 2007 Jan;66(1):23-7 [16569685.001]

[Cites] JAMA. 2006 Dec 20;296(23):2823-31 [17179459.001]

[Cites] Nat Med. 2007 Feb;13(2):139-45 [17290272.001]

[Cites] Blood. 2007 Mar 15;109(6):2545-52 [17132718.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3207-12 [17360630.001]

[Cites] Transl Res. 2007 Apr;149(4):231-5 [17383597.001]

[Cites] J Virol. 2007 Jun;81(11):5872-81 [17392362.001]

[Cites] J Immunol. 2007 Jun 1;178(11):6730-3 [17513719.001]

[Cites] Nucleic Acids Res. 2007;35(10):e73 [17478510.001]

[Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]

[Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]

[Cites] J Immunol. 2007 Sep 1;179(5):3153-60 [17709530.001]

[Cites] AIDS. 2007 Nov 12;21(17):2265-70 [18090274.001]

[Cites] Nat Genet. 2008 Jan;40(1):108-12 [18066064.001]

[Cites] Cancer Res. 2008 Mar 1;68(5):1436-42 [18316607.001]

[Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]

[Cites] J Immunol. 2008 Jul 1;181(1):186-9 [18566383.001]

[Cites] Blood. 2008 Dec 1;112(12):4401-10 [18780835.001]

[Cites] Ann Rheum Dis. 2009 Jan;68(1):89-93 [18375535.001]

[Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]

[Cites] Int J Cancer. 2009 Apr 15;124(8):1745-55 [19165855.001]

[Cites] J Clin Oncol. 2009 Feb 20;27(6):967-73 [19114696.001]

[Cites] J Infect Dis. 2009 Jul 1;200(1):79-87 [19476437.001]

[Cites] Clin Cancer Res. 2009 Oct 1;15(19):5968-73 [19773382.001]

[Cites] Biochem Biophys Res Commun. 2009 Dec 11;390(2):269-72 [19799865.001]

[Cites] Mol Immunol. 2009 Nov;47(1):3-7 [19193443.001]

[Cites] Mol Cell. 2009 Nov 25;36(4):631-41 [19941823.001]

[Cites] Semin Cancer Biol. 2009 Dec;19(6):351-65 [19619654.001]

[Cites] Semin Cancer Biol. 2009 Dec;19(6):401-6 [19619656.001]

[Cites] Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22421-6 [20080792.001]

[Cites] Int J Cancer. 2010 Mar 15;126(6):1316-26 [19530237.001]

[Cites] J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):170-9 [19654554.001]

[Cites] J Clin Oncol. 2010 Feb 10;28(5):773-9 [20048176.001]

[Cites] Cytokine. 2010 Apr;50(1):58-68 [20060740.001]

[Cites] J Leukoc Biol. 2010 Apr;87(4):627-32 [20042471.001]

[Cites] AIDS. 2010 Apr 24;24(7):1025-33 [20299965.001]

[Cites] J Acquir Immune Defic Syndr. 2010 May 1;54(1):18-26 [20216076.001]

[Cites] Cancer Immunol Immunother. 2010 Jul;59(7):979-87 [20352428.001]

[Cites] Br J Haematol. 2010 May;149(4):484-97 [20346013.001]

[Cites] Biochem Biophys Res Commun. 2010 May 21;396(1):67-73 [20494113.001]

[Cites] PLoS One. 2010;5(7):e11448 [20625427.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):979-84 [10566552.001]

[Cites] Inflamm Bowel Dis. 1999 Nov;5(4):285-94 [10579123.001]

[Cites] Clin Immunol. 1999 Dec;93(3):239-44 [10600334.001]

[Cites] J Allergy Clin Immunol. 2000 May;105(5):975-82 [10808179.001]

[Cites] AIDS. 2000 Jul 7;14(10):1460-1 [10930167.001]

(PMID = 20717742.001).

[ISSN] 1559-0755

[Journal-full-title] Immunologic research

[ISO-abbreviation] Immunol. Res.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / R01 CA073475

[Publication-type] Journal Article; Review

[Publication-country] United States

[Other-IDs] NLM/ NIHMS461037; NLM/ PMC3640300

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Physician perceptions and preferences in the treatment of acquired immunodeficiency syndrome (AIDS)-related lymphoma.

The optimal management of acquired immunodeficiency syndrome-related lymphoma (ARL) in the era of combination antiretroviral therapy (cART) is unclear.

Of 196 lymphoma-treating physicians, 117 (63%) responded.

[MeSH-major] Lymphoma, AIDS-Related / drug therapy. Physicians / psychology. Practice Patterns, Physicians' / statistics & numerical data

[MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / utilization. Canada. Choice Behavior. Cyclophosphamide / therapeutic use. Data Collection. Disease Management. Doxorubicin / therapeutic use. Humans. Prednisone / therapeutic use. Rituximab. Vincristine / therapeutic use

Genetic Alliance. consumer health - AIDS-HIV.

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17372734.001).

[ISSN] 0939-5555

[Journal-full-title] Annals of hematology

[ISO-abbreviation] Ann. Hematol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Autologous stem cell transplantation using MEAM regimen for relapsed AIDS-related lymphoma patients who received highly active anti-retroviral therapy: a report of three cases.

AIDS-related lymphoma (ARL) is a serious complication of HIV infection.

[MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / therapy. Transplantation Conditioning / methods

[MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antiretroviral Therapy, Highly Active. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. HIV Infections / drug therapy. Humans. Male. Melphalan / administration & dosage. Nitrosourea Compounds / administration & dosage. Recurrence. Salvage Therapy. Transplantation, Autologous

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Transplantation.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. MELPHALAN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19145056.001).

[ISSN] 1349-7235

[Journal-full-title] Internal medicine (Tokyo, Japan)

[ISO-abbreviation] Intern. Med.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Nitrosourea Compounds; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; RYH2T97J77 / ranimustine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV-associated lymphoma: the evidence for treating aggressively but with caution.

PURPOSE OF THE REVIEW: The aim of this article is to review key reports regarding the biology and management of HIV-associated lymphoma during the past year.

RECENT FINDINGS: The use of highly active antiretroviral therapy (HAART) has been associated with a reduced risk of primary cerebral and systemic non-Hodgkin's lymphoma, a stable or slightly increased risk of Hodgkin's lymphoma, and improved prognosis for those who develop HIV-associated non-Hodgkin's lymphoma or Hodgkin's lymphoma.

Emerging evidence suggests that patients with HIV-associated lymphoma should be treated in a similar manner as immunocompetent patients with the same disease, especially if the CD4 count is 50-100 cells/mul or higher.

Use of the anti-CD20 monoclonal antibody rituximab in combination with chemotherapy appears to result in improved control of B-cell lymphoma, but may come at the expense of an increased risk of bacterial and viral infections.

SUMMARY: Although the evidence currently supports an aggressive and curative approach for the management of HIV-associated lymphoma, clinicians must be vigilant about implementing infection prophylaxis and promptly recognizing, diagnosing, and treating bacterial, parasitic, fungal, and viral infections that may occur as a consequence of therapy.

[MeSH-major] HIV. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17762571.001).

[ISSN] 1040-8746

[Journal-full-title] Current opinion in oncology

[ISO-abbreviation] Curr Opin Oncol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 39

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Radiation therapy for HIV-associated diffuse large cell non-Hodgkin lymphoma.

PURPOSE: To report the clinical experience with external beam radiotherapy (RT) for AIDS-related lymphoma (ARL) with or without the involvement of the central nervous system (CNS) in HIV-infected patients.

PATIENTS AND METHODS: Clinical outcome of 24 HIV-seropositive patients with ARL treated with RT from 1995 to 2004 was reviewed, testing factors associated with outcome.

Radiotherapy dose was associated with survival in univariate (P = .04) and multivariate analysis (P = .01).

Other factors in univariate analysis associated with outcome were viral load (VL), highly active antiretroviral therapy (HAART), ARL stage, and CNS involvement.

[MeSH-major] Lymphoma, AIDS-Related / radiotherapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy

[MeSH-minor] Adult. Aged. CD4 Lymphocyte Count. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / mortality. Central Nervous System Neoplasms / radiotherapy. Chemotherapy, Adjuvant. Female. HIV Seropositivity. Humans. Male. Middle Aged. Radiotherapy Dosage. Survival Analysis. Viral Load

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Lymphoma, large-cell.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

Genetic Alliance. consumer health - HIV.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19589920.001).

[ISSN] 1545-1097

[Journal-full-title] Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)

[ISO-abbreviation] J Int Assoc Physicians AIDS Care (Chic)

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Autologous stem-cell transplantation in patients with HIV-related lymphoma.

PURPOSE: Peripheral-blood autologous stem-cell transplantation (ASCT) in patients with HIV-related lymphoma (HIV-Ly) has been reported as a safe and useful procedure.

Herein we report the European Group for Blood and Marrow Transplantation experience on patients with HIV-Ly undergoing ASCT.

RESULTS: Since 1999, 68 patients from 20 institutions (median age, 41 years; range, 29 to 62 years) were included, diagnosed with non-Hodgkin's lymphoma (NHL; n = 50) or Hodgkin's lymphoma (n = 18).

At the time of ASCT, 16 patients were in first complete remission (CR1); 44 patients were in CR more than 1, partial remission, or chemotherapy-sensitive relapse (chemo-S); and eight patients had chemotherapy-resistant disease.

CI of relapse was 30.4% at 24 months, statistically related with not being in CR at ASCT (relative risk [RR] = 3.6), NHL histology other than diffuse large B-cell lymphoma (RR = 3.4), and use of more than two previous treatment lines (RR = 3).

Patients not in CR or with refractory disease at ASCT had poorer PFS (RR = 2.4 and 4.8, respectively).

CONCLUSION: Similarly to HIV-negative patients with lymphoma, ASCT is a useful treatment for patients with HIV-Ly and is associated with low NRM, mainly when performed in early stages and chemo-S disease.

[MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / therapy

Genetic Alliance. consumer health - Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[ErratumIn] J Clin Oncol. 2009 Jul 1;27(19):3263

(PMID = 19332732.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.

AIDS patients who develop lymphoma are often treated with transplanted hematopoietic progenitor cells.

As a first step in developing a hematopoietic cell-based gene therapy treatment, four patients undergoing treatment with these transplanted cells were also given gene-modified peripheral blood-derived (CD34(+)) hematopoietic progenitor cells expressing three RNA-based anti-HIV moieties (tat/rev short hairpin RNA, TAR decoy, and CCR5 ribozyme).

In vitro estimates of successful expression of the anti-HIV moieties were initially as high as 22% but declined to approximately 1% over 4 weeks of culture.

Transfected cells were successfully engrafted in all four infused patients by day 11, and there were no unexpected infusion-related toxicities.

These results support the development of an RNA-based cell therapy platform for HIV.

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Transplantation.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Genes and Gene Therapy.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Biotechnol. 2007 Dec;25(12):1444-54 [18066041.001]

[Cites] Mol Ther. 2007 Jun;15(6):1182-8 [17406343.001]

[Cites] Hum Gene Ther. 2008 Jun;19(6):622-34 [18533892.001]

[Cites] J Gene Med. 2008 Oct;10(10):1059-70 [18642399.001]

[Cites] Gene Ther. 2008 Dec;15(23):1536-49 [18800151.001]

[Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]

[Cites] Nat Med. 2009 Mar;15(3):285-92 [19219022.001]

[Cites] Science. 2009 Mar 6;323(5919):1304-7 [19265012.001]

[Cites] Mol Ther. 2009 May;17(5):844-50 [19259065.001]

[Cites] Science. 2009 Nov 6;326(5954):818-23 [19892975.001]

[Cites] Gene Ther. 2010 Mar;17(3):389-99 [19865182.001]

[Cites] Blood. 2002 Jan 15;99(2):698-701 [11781257.001]

[Cites] Mol Ther. 2002 Apr;5(4):479-84 [11945076.001]

[Cites] Gene Ther. 2002 Aug;9(16):1055-64 [12140733.001]

[Cites] Gene Ther. 2002 Dec;9(24):1730-4 [12457288.001]

[Cites] Mol Ther. 2003 Mar;7(3):325-33 [12668128.001]

[Cites] Mol Ther. 2003 Jul;8(1):62-71 [12842429.001]

[Cites] Mol Ther. 2003 Aug;8(2):196-206 [12907142.001]

[Cites] Blood. 2004 Feb 1;103(3):796-803 [12920024.001]

[Cites] Hum Gene Ther. 2004 Mar;15(3):251-62 [15018734.001]

[Cites] J Gene Med. 2004 Mar;6(3):268-77 [15026988.001]

[Cites] Nature. 1988 Sep 29;335(6189):395-6 [3166513.001]

[Cites] Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9870-4 [1409715.001]

[Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]

[Cites] Blood. 1994 Jul 15;84(2):421-32 [7517715.001]

[Cites] Science. 1996 Apr 12;272(5259):263-7 [8602510.001]

[Cites] Blood. 1996 Jun 1;87(11):4618-28 [8639830.001]

[Cites] Gene Ther. 1996 Aug;3(8):717-24 [8854097.001]

[Cites] J Virol. 1997 Jun;71(6):4707-16 [9151864.001]

[Cites] J Virol. 1999 May;73(5):3649-60 [10196257.001]

[Cites] Blood. 2005 Jan 15;105(2):874-8 [15388574.001]

[Cites] Clin Immunol. 2005 Apr;115(1):26-32 [15870017.001]

[Cites] Mol Ther. 2005 Jul;12(1):77-86 [15963923.001]

[Cites] Mol Ther. 2005 Oct;12(4):697-706 [16039909.001]

[Cites] Mol Ther. 2005 Nov;12(5):900-9 [16115802.001]

[Cites] Mol Ther. 2006 Feb;13(2):366-73 [16325473.001]

[Cites] Blood. 2006 Mar 1;107(5):1751-60 [16269617.001]

[Cites] Clin Infect Dis. 2006 Apr 1;42(7):1003-10 [16511767.001]

[Cites] Mol Ther. 2006 Oct;14(4):494-504 [16844419.001]

[Cites] Blood. 2006 Nov 15;108(10):3305-12 [16857988.001]

[Cites] Mol Ther. 2007 May;15(5):1024-33 [17356541.001]

[Cites] Methods Mol Biol. 2008;434:99-112 [18470641.001]

(PMID = 20555022.001).

[ISSN] 1946-6242

[Journal-full-title] Science translational medicine

[ISO-abbreviation] Sci Transl Med

[Language] ENG

[Grant] United States / NCRR NIH HHS / RR / M01 RR000043-49; United States / NIAID NIH HHS / AI / AI61839; United States / NHLBI NIH HHS / HL / R01 HL074704; United States / NIAID NIH HHS / AI / AI42552; United States / NCI NIH HHS / CA / CA107399-05; United States / NIAID NIH HHS / AI / P01 AI061839-04; United States / NIAID NIH HHS / AI / R37 AI029329; United States / NCRR NIH HHS / RR / RR000043-49; United States / NIAID NIH HHS / AI / AI061839-04; United States / NHLBI NIH HHS / HL / HL07470; United States / NCI NIH HHS / CA / P50 CA107399-05; United States / NCRR NIH HHS / RR / M01 RR00043; United States / NCRR NIH HHS / RR / RR025083-01; United States / NCI NIH HHS / CA / P30 CA33572-26; United States / NCRR NIH HHS / RR / S10 RR025083-01; United States / NIAID NIH HHS / AI / AI042552-11; United States / NCI NIH HHS / CA / P30 CA033572-29; United States / NCRR NIH HHS / RR / M01 RR000043; United States / NHLBI NIH HHS / HL / R01 HL074704-07; United States / NIAID NIH HHS / AI / P01 AI061839; United States / NCI NIH HHS / CA / P30 CA033572; United States / NIAID NIH HHS / AI / R01 AI042552; United States / NCRR NIH HHS / RR / S10 RR025083; United States / NIAID NIH HHS / AI / R01 AI042552-11; United States / NCRR NIH HHS / RR / S10RR025083-01; United States / NHLBI NIH HHS / HL / HL074704-07; United States / NCI NIH HHS / CA / P50 CA107399

[Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 63231-63-0 / RNA

[Other-IDs] NLM/ NIHMS305014; NLM/ PMC3130552

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Morphological spectrum of AIDS-related plasmablastic lymphomas.

We have had a recent spurt in cases of AIDS-related lymphoma (ARL) at our centre.

Most of these cases are aggressive mature B cell lymphomas, mainly plasmablastic lymphoma (PBL) and diffuse large B-cell lymphoma (DLBCL).

Diagnosis was based on morphology, immunohistochemistry, proliferation index, HIV positive status and its preference to extranodal sites (mostly mucosa based).

[MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lymphoma, AIDS-Related / pathology

[MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / analysis. Antigens, CD45 / analysis. Burkitt Lymphoma / pathology. Child. Female. Humans. Immunoglobulin Light Chains / analysis. Leukemia, Plasma Cell / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology. Male. Middle Aged. Syndecan-1 / analysis

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18417882.001).

[ISSN] 0377-4929

[Journal-full-title] Indian journal of pathology & microbiology

[ISO-abbreviation] Indian J Pathol Microbiol

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

[Chemical-registry-number] 0 / Antigens, CD20; 0 / Immunoglobulin Light Chains; 0 / SDC1 protein, human; 0 / Syndecan-1; EC 3.1.3.48 / Antigens, CD45

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV-miR-H1 evolvability during HIV pathogenesis.

Two early studies found no detectable miRNAs expressed within HIV; however, several studies have verified the existence and function of three HIV miRNAs, most notably HIV-miR-TAR, thus making the earlier results controversial.

Although miRNAs are highly conserved within most species, HIV is known to have a high mutation rate, which could contribute to the opposing experimental findings and raises questions about whether all HIV miRNAs are robust enough to maintain their integrity, especially in viral regions prone to insertions and deletions.

In addition, could the evolvability of HIV miRNAs contribute to the diversity in HIV disease pathogenesis?

To address this question, we examined mutations in 1293 sequences in a suspect HIV miRNA, called miR-H1, derived from a large variety of tissues from seven patients.

We also note a potential disease association between a less stable miR-H1 and the development of AIDS-related lymphoma (ARL).

MedlinePlus Health Information. consumer health - HIV/AIDS.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nucleic Acids Res. 2008 Apr;36(7):2353-65 [18299284.001]

[Cites] PLoS Pathog. 2007 Nov;3(11):e163 [17983268.001]

[Cites] J Soc Biol. 2007;201(4):377-84 [18533098.001]

[Cites] Mol Phylogenet Evol. 2008 Nov;49(2):618-28 [18801446.001]

[Cites] Retrovirology. 2008;5:112 [19077215.001]

[Cites] Mol Cell Biochem. 2009 Mar;323(1-2):143-8 [19082544.001]

[Cites] Drug News Perspect. 2008 Sep;21(7):369-81 [19259550.001]

[Cites] Retrovirology. 2009;6:18 [19220914.001]

[Cites] PLoS One. 2009;4(3):e5065 [19333384.001]

[Cites] Clin Infect Dis. 2009 Sep 1;49(5):780-6 [19622045.001]

[Cites] PLoS One. 2009;4(12):e8153 [19997510.001]

[Cites] J Med Virol. 2000 Jun;61(2):171-80 [10797371.001]

[Cites] AIDS. 2000 Dec 22;14(18):2937-9 [11153675.001]

[Cites] J Hered. 2001 Jul-Aug;92(4):371-3 [11535656.001]

[Cites] J Virol. 2002 Apr;76(8):3852-64 [11907225.001]

[Cites] Cancer Res. 2002 Oct 1;62(19):5536-42 [12359765.001]

[Cites] Nucleic Acids Res. 2003 Jan 1;31(1):439-41 [12520045.001]

[Cites] Science. 2003 Mar 7;299(5612):1540 [12624257.001]

[Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3406-15 [12824337.001]

[Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D109-11 [14681370.001]

[Cites] Science. 2004 Apr 30;304(5671):734-6 [15118162.001]

[Cites] Neurobiol Dis. 2004 Jun;16(1):150-7 [15207272.001]

[Cites] AIDS. 1994 Aug;8(8):1025-49 [7986399.001]

[Cites] Nucleic Acids Res. 1997 Jan 1;25(1):1-6 [9016491.001]

[Cites] Clin Rev Allergy Immunol. 1996-1997 Winter;14(4):359-66 [9040966.001]

[Cites] Virology. 1997 Jun 9;232(2):319-31 [9191845.001]

[Cites] Immunol Rev. 1998 Apr;162:293-8 [9602372.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Oct 1;19(2):99-110 [9768617.001]

[Cites] J Gen Virol. 2005 Mar;86(Pt 3):751-5 [15722536.001]

[Cites] Nature. 2005 Apr 14;434(7035):864-70 [15829956.001]

[Cites] Nature. 2005 Apr 14;434(7035):907-13 [15829965.001]

[Cites] Nat Methods. 2005 Apr;2(4):269-76 [15782219.001]

[Cites] Retrovirology. 2004;1:43 [15601472.001]

[Cites] Retrovirology. 2004;1:44 [15601474.001]

[Cites] PLoS Pathog. 2006 Mar;2(3):e23 [16557291.001]

[Cites] Virus Res. 2006 Nov;121(2):107-15 [16889864.001]

[Cites] Mol Biol Evol. 2007 Aug;24(8):1596-9 [17488738.001]

[Cites] BMC Mol Biol. 2007;8:63 [17663774.001]

[Cites] J Neurovirol. 2007 Aug;13(4):291-304 [17849313.001]

[Cites] PLoS Pathog. 2007 Sep 7;3(9):1281-90 [17907802.001]

[Cites] J Virol. 2007 Nov;81(22):12218-26 [17855543.001]

[Cites] J Cell Physiol. 2008 Aug;216(2):321-6 [18484093.001]

(PMID = 20546828.001).

[ISSN] 1872-8324

[Journal-full-title] Bio Systems

[ISO-abbreviation] BioSystems

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / U01 CA066529; United States / NCI NIH HHS / CA / U01 CA096230; United States / NCI NIH HHS / CA / U01 CA066529-14; United States / NCI NIH HHS / CA / U01 CA096230-06

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] Ireland

[Chemical-registry-number] 0 / HIV Envelope Protein gp120; 0 / MicroRNAs

[Other-IDs] NLM/ NIHMS407806; NLM/ PMC3478900

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Modern management of non-Hodgkin lymphoma in HIV-infected patients.

Patients infected with human immunodeficiency virus (HIV) are at greater risk of developing non-Hodgkin lymphoma than the general population and aggressive B-cell lymphoma has become one of the most common of the initial acquired immunodeficiency syndrome (AIDS)-defining illnesses.

This review considers the prognostic factors and new approaches to the treatment of patients with AIDS-related lymphoma (ARL).

As highly active antiretroviral therapy (HAART) became available, the survival of many ARL patients has become comparable to that of HIV-negative patients.

Both developments can also be attributed to new treatment strategies for ARL, such as the use of effective infusional regimens, Rituximab combinations and high-dose therapy with autologous stem-cell transplantation for relapsed disease.

[MeSH-major] Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

[MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antiretroviral Therapy, Highly Active. Burkitt Lymphoma / drug therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Hematopoietic Stem Cell Transplantation. Humans. Prognosis. Rituximab

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17229246.001).

[ISSN] 0007-1048

[Journal-full-title] British journal of haematology

[ISO-abbreviation] Br. J. Haematol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab

[Number-of-references] 83

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy.

We aimed to compare AIDS risk-adapted intensive chemotherapy in AIDS-related lymphoma (ARL) patients before and after the advent of highly active antiretroviral therapy (HAART).

A total of 485 patients aged from 18 to 67 years were randomly assigned to chemotherapy after stratification according to an HIV score based on performance status, prior AIDS, and CD4(+) cell counts below 0.10 x 10(9)/L (100/mm(3)).

A total of 218 good-risk patients (HIV score 0) received ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisolone) or CHOP (doxorubicin, cyclophosphamide, vincristine, and prednisolone); 177 intermediate-risk patients (HIV score 1), CHOP or low-dose CHOP (Ld-CHOP); and 90 poor-risk patients (HIV score 2-3), Ld-CHOP or VS (vincristine and steroid).

The time-dependent Cox model demonstrated that the only significant factors for OS were HAART (relative risk [RR] 1.6, P < .001), HIV score (RR 1.7, P < .001), and the International Prognostic Index (IPI) score (RR 1.5, P < .001) but not chemotherapy regimen.

Our findings indicate that in ARL patients, HIV score, IPI score, and HAART affect survival but not the intensity of the CHOP-based chemotherapy.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISOLONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Blood. 2006 Nov 15;108(10):3621; author reply 3621-2 [17085718.001]

(PMID = 16410446.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Plasma Epstein-Barr viral load measurement as a diagnostic marker of lymphoma in HIV-infected patients.

BACKGROUND AND OBJECTIVES: To assess the use of the Epstein-Barr virus (EBV) viral load as a marker for lymphoma diagnosis in HIV-infected patients.

We also aimed to identify the relationship between EBV viral load in plasma and the presence of EBV in lymphoma cells.

PATIENTS AND METHODS: Retrospective observational study of two HIV-infected populations: one of patients diagnosed with lymphoma and a control group.

Thirty-nine patients with AIDS-related lymphoma (ARL) (32 non-Hodgkin's and 7 Hodgkin's lymphomas) and 134 HIV-positive individuals without neoplasia or opportunistic infections were studied.

Blood samples were collected before lymphoma treatment in ARL patients.

EBV viral load was measured in plasma by real-time quantitative PCR and the presence of EBV-EBER mRNA in lymphoma tumor was investigated by in situ hybridization.

RESULTS: Patients with ARL had higher EBV viral loads than those without lymphoma: 24,180.5 (±73,387.6)copies/mL versus 2.6 (±21.6)copies/mL (p<0.001).

HIV-infected patients without lymphoma had negative or very low EBV load values.

Among ARL patients, no correlation was found between EBV viral loads and CD4+ lymphocyte counts or between EBV and HIV RNA loads, or any other clinical or biological parameter.

Cases with an EBV-EBER-positive lymphoma had higher EBV viral loads than those with EBER-negative tumors.

CONCLUSIONS: EBV viral load is a useful marker of lymphoma in HIV-infected patients, and may be a useful tool for early diagnosis and treatment.

[MeSH-major] Herpesvirus 4, Human. Lymphoma, AIDS-Related / blood. Lymphoma, AIDS-Related / diagnosis. Viral Load

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2009 Elsevier España, S.L. All rights reserved.

(PMID = 20673682.001).

[ISSN] 0025-7753

[Journal-full-title] Medicina clínica

[ISO-abbreviation] Med Clin (Barc)

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Spain

[Chemical-registry-number] 0 / Biomarkers

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma.

BACKGROUND: One of the major concern for high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT) for HIV-associated lymphoma is that posttransplant immunosuppression might worsen immune defects of HIV individuals.

Since the introduction of highly active antiretroviral therapy has made HSCT possible also in these patients, we analyzed whether the immune system already compromised by HIV infection might support an efficient T-cell recovery after HSCT.

METHODS: The kinetics and the extent of T-cell reconstitution were investigated before and after HSCT in four patients with HIV-related lymphoma (one with Hodgkin's Disease and three with non-Hodgkin's lymphoma) by measuring the thymic output, the level of IL-7 and the heterogeneity of T-cell repertoire.

CONCLUSIONS: High-dose therapy and HSCT in HIV patients under highly active antiretroviral therapy does not worsen the immune defects.

[MeSH-major] CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / therapy

Genetic Alliance. consumer health - Transplantation.

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Transplantation. 2006 Jun 27;81(12):1752-3 [16794547.001]

(PMID = 16177644.001).

[ISSN] 0041-1337

[Journal-full-title] Transplantation

[ISO-abbreviation] Transplantation

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, alpha-beta